Picture loading failed.

Anti-IL1RL1 therapeutic antibody (Pre-made Melrilimab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Melrilimab (formerly GSK 3772847) was a monoclonal antibody targeting interleukin-1 receptor-like 1 (IL1RL1 or ST2 or IL-33R), which was being developed by GlaxoSmithKline for the treatment of asthma and atopic dermatitis. Clinical development was ongoing in the US and the UK.

Order information


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-340-1mg 1mg 3090
GMP-Bios-ab-340-10mg 10mg 21890
GMP-Bios-ab-340-100mg 100mg 148000
GMP-Bios-ab-340-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-IL1RL1 therapeutic antibody (Pre-made Melrilimab biosimilar,Whole mAb)
INN Name Melrilimab
TargetIL1RL1
FormatWhole mAb
Derivation
Species ReactivityHuman
CH1 IsotypeIgG2
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-II
Est. StatusDiscontinued
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2020
Year Recommended2021
CompaniesGlaxoSmithKline
Conditions Approvedna
Conditions Activena
Conditions DiscontinuedAsthma;Atopic dermatitis
Development Techna